Novo Nordisk AS (NOVO B)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Novo Nordisk AS (NOVO B) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011128
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月21日
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Novo Nordisk A/S (Novo Nordisk), a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company’s product portfolio includes new-generation insulins, modern insulins, human insulins, oral antidiabetic agents, diabetes devices and others. Novo Nordisk also offers biopharmaceuticals for treating haemostasis, human growth hormone products and hormone replacement therapy. With subsidiaries in Europe, North America, Asia, Latin America and Australia, it markets its products in several countries worldwide. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

Novo Nordisk AS (NOVO B) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Novo Nordisk AS, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Novo Nordisk AS, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Novo Nordisk AS, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Novo Nordisk AS, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Novo Nordisk AS, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Novo Nordisk AS, Medical Equipment, Deal Details 12
Venture Financing 12
Ra Pharma Raises USD58.5 Million in Series B Financing 12
Cianna Medical Raises USD4 Million in Venture Financing Round 14
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 15
Nevro Raises US$48 Million In Series C Financing 16
Ceterix Orthopaedics Raises US$19.5 Million In Series B Financing 18
Cianna Medical Secures US$12 Million In Series B Financing 19
Partnerships 20
Novo Nordisk Enters into Agreement with Glooko 20
Novo Nordisk Enters into Agreement with IBM Watson Health 21
Novo Nordisk Enters into Research Agreement with Massachusetts Institute of Technology 22
BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 23
Novo Nordisk Enters Into Co-Development Agreement With Oxford University 24
Equity Offering 25
NNIT Prices IPO for USD191 Million 25
Novo Nordisk AS – Key Competitors 27
Novo Nordisk AS – Key Employees 28
Novo Nordisk AS – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 35
Strategy And Business Planning 35
Sep 29, 2016: Novo Nordisk announces plans to reduce workforce by approximately 1,000 employees 35
Aug 05, 2016: Caverion delivers a Large Project for Novo Nordisk’s new insulin production facility in Hillerod, Denmark 36
Financial Announcements 37
Nov 01, 2017: Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017 37
Aug 09, 2017: Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 38
May 03, 2017: Novo Nordisk increased reported operating profit by 10% in the first three months of 2017 39
Feb 02, 2017: Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016 40
Oct 28, 2016: Novo Nordisk increased adjusted operating profit by 7% in local currencies in the first nine months of 2016 41
Aug 05, 2016: Novo Nordisk increased adjusted operating profit by 8% in local currencies in the first six months of 2016 42
Apr 29, 2016: Novo Nordisk increased adjusted operating profit by 10% in local currencies in the first quarter of 2016 43
Feb 03, 2016: Novo Nordisk increased operating profit by 43% in 2015 to DKK 49.4 billion 44
Corporate Communications 45
Aug 15, 2017: Changes in Novo Nordisk Executive Management 45
May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 46
May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 47
Mar 01, 2017: Change in Novo Nordisk Executive Management 48
Sep 01, 2016: Lars Rebien Sorensen to retire as CEO of Novo Nordisk; Lars Fruergaard Jorgensen appointed as successor 49
Feb 12, 2016: Proposed changes in composition of the Board of Directors of Novo Nordisk 51
Other Significant Developments 52
Sep 26, 2017: Novo Nordisk Teams Up with HITLAB to Challenge Innovators to Develop Voice-Activated Technology for Diabetes Care with $75,000 in Prizes 52
Jul 12, 2017: Novo Nordisk and Glooko advance their digital health collaboration with launch of unique integrated app for improved diabetes management 53
Aug 05, 2016: Caverion delivers a Large Project for Novo Nordisk’s new insulin production facility in Hillerod, Denmark 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Novo Nordisk AS, Medical Equipment, Key Facts, 2016 2
Novo Nordisk AS, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Novo Nordisk AS, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Novo Nordisk AS, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Novo Nordisk AS, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Novo Nordisk AS, Deals By Market, 2011 to YTD 2017 9
Novo Nordisk AS, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Ra Pharma Raises USD58.5 Million in Series B Financing 12
Cianna Medical Raises USD4 Million in Venture Financing Round 14
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 15
Nevro Raises US$48 Million In Series C Financing 16
Ceterix Orthopaedics Raises US$19.5 Million In Series B Financing 18
Cianna Medical Secures US$12 Million In Series B Financing 19
Novo Nordisk Enters into Agreement with Glooko 20
Novo Nordisk Enters into Agreement with IBM Watson Health 21
Novo Nordisk Enters into Research Agreement with Massachusetts Institute of Technology 22
BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 23
Novo Nordisk Enters Into Co-Development Agreement With Oxford University 24
NNIT Prices IPO for USD191 Million 25
Novo Nordisk AS, Key Competitors 27
Novo Nordisk AS, Key Employees 28
Novo Nordisk AS, Subsidiaries 29

★海外企業調査レポート[Novo Nordisk AS (NOVO B)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Boston Children’s Hospital:医療機器:M&Aディール及び事業提携情報
    Summary Boston Children's Hospital (Boston Children’s) is the pediatric medical center that provides a comprehensive range of health care services for children from birth through 21 years of age. Boston Children’s is the primary pediatric teaching affiliate of Harvard Medical School. The organizatio …
  • Royal IHC:石油・ガス:M&Aディール及び事業提携情報
    Summary Royal IHC (IHC), formerly IHC Merwede BV is a shipbuilding company that offers engineering solutions. The company’s product portfolio includes dredging equipment, motion control and automation equipment, decommissioning equipment, offshore foundation equipment and metal construction kits. IH …
  • Autoliv Inc (ALV):企業の財務・戦略的SWOT分析
    Autoliv Inc (ALV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • International SOS Pte Ltd:企業の戦略的SWOT分析
    International SOS Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Encavis AG (CAP):企業の財務・戦略的SWOT分析
    Summary Encavis AG (Encavis), formally Capital Stage AG, is an independent power producer. It offer investment services such as asset sourcing, due diligence, management, and documentation of renewable energy assets. Encavis also provides technical services comprising monitoring, reporting, fault ma …
  • Red Hill Iron Limited:企業の戦略・SWOT・財務分析
    Red Hill Iron Limited - Strategy, SWOT and Corporate Finance Report Summary Red Hill Iron Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Carnival Corporation & plc:企業の戦略・SWOT・財務情報
    Carnival Corporation & plc - Strategy, SWOT and Corporate Finance Report Summary Carnival Corporation & plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Spark Therapeutics Inc (ONCE):企業の財務・戦略的SWOT分析
    Summary Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1 …
  • Essential Energy Services Ltd (ESN):石油・ガス:M&Aディール及び事業提携情報
    Summary Essential Energy Services Ltd (Essential Energy) is an oil and gas company that offers oilfield services. The company provides coil well services and tool services. Its services include coil tubing, fluid and nitrogen pumping, completion, abandonment, and downhole tools and equipment rental …
  • Vericel Corp (VCEL):企業の財務・戦略的SWOT分析
    Vericel Corp (VCEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Adamas Pharmaceuticals Inc (ADMS):製薬・医療:M&Aディール及び事業提携情報
    Summary Adamas Pharmaceuticals Inc (Adamas Pharmaceuticals) is a pharmaceutical company that develops and commercializes therapeutics for chronic disorders of the central nervous system. The company's Gocovri, formerly ADS-5102, is an amantadine extended-release (XR) formulation for the treatment fo …
  • BW Offshore Ltd (BWO):企業の財務・戦略的SWOT分析
    BW Offshore Ltd (BWO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • SeaSpine Holdings Corporation (SPNE):企業の財務・戦略的SWOT分析
    SeaSpine Holdings Corporation (SPNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Heidelberger Druckmaschinen AG (HDD):企業の財務・戦略的SWOT分析
    Heidelberger Druckmaschinen AG (HDD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Superior Energy Services Inc Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Superior Energy Services Inc Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Superior Energy Services Inc (Superior Energy) is a provider of equipment and production services to the energy industry. It offers drilling, completion and production-related services to in …
  • MILEI GmbH:企業の戦略・SWOT・財務情報
    MILEI GmbH - Strategy, SWOT and Corporate Finance Report Summary MILEI GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • 3M India Limited (3MINDIA):企業の財務・戦略的SWOT分析
    3M India Limited (3MINDIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • BNP Paribas SA:企業のM&A・事業提携・投資動向
    BNP Paribas SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BNP Paribas SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Coca-Cola Consolidated Inc (COKE):企業の財務・戦略的SWOT分析
    Coca-Cola Consolidated Inc (COKE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • ThyssenKrupp AG:企業の戦略・SWOT・財務分析
    ThyssenKrupp AG - Strategy, SWOT and Corporate Finance Report Summary ThyssenKrupp AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆